Pulmonary Hypertension Clinical Trial
Official title:
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Verified date | February 2016 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that has no proven effective treatment. This study assessed the effects of acute nitrite administration on resting and exercise hemodynamics in patients with HFpEF.
Status | Completed |
Enrollment | 28 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Scheduled to undergo a cardiac catheterization procedure. - Clinical symptoms of shortness of breath and fatigue - Normal left ventricular ejection fraction (=50%) - Elevated left ventricular filling pressures at cardiac catheterization (defined as resting pulmonary capillary wedge pressure (PCWP)>15 mmHg and/or PCWP=25 mmHg during exercise) Exclusion Criteria: - Systolic BP <120 mmHg - Prior nitrate therapy (within previous 2 weeks) - Glucose 6-phosphate dehydrogenase (G6PD) deficiency - Other "non-HFpEF" specific causes of heart failure such as significant valvular disease (>moderate left-sided regurgitation, >mild stenosis), severe pulmonary disease, unstable coronary disease or coronary spasm, primary renal or hepatic disease, constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Barry Borlaug |
United States,
Borlaug BA, Koepp KE, Melenovsky V. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2015 Oct 13;66(15):1672-82. doi: 10.1016/j.jacc.2015.07.067. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exercise Pulmonary Capillary Wedge Pressure (PCWP) | Pulmonary capillary wedge pressure (PCWP) provides an indirect estimate of left atrial pressure (LAP). PCWP is the pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch. | during repeat exercise run, approximately 30 minutes after study drug administration | No |
Secondary | Change in Central Pressures After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Heart Rate After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Blood Pressure After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Pulmonary Vascular Resistance (PVR) After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Pulmonary Vascular Resistance (PVR) is the resistance to flow that must be overcome to push blood through the pulmonary vasculature. Acute and chronic lung disease can both cause an increase in PVR. Chronic PVR can lead to right sided heart failure. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Pulmonary Artery (PA) Compliance After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Pulmonary artery compliance is an index of the elasticity of the blood vessel, an indication of arterial stiffness. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Systemic Vascular Resistance (SVR) After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Systemic vascular resistance (SVR) refers to the resistance to blood flow offered by all of the systemic vasculature, excluding the pulmonary vasculature. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Left Ventricular Stroke Work (LVSW) After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Stroke work refers to the work done by the ventricle to eject a volume of blood (i.e., stroke volume) into the aorta. Ventricular stroke work can be estimated as the product of stroke volume and mean aortic pressure during ejection. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Oxygen Consumption (VO_2) After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Arteriovenous Oxygen Content Difference After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Arteriovenous oxygen difference is the difference in the oxygen content of the blood between the arterial blood and the venous blood. It is an indication of how much oxygen is removed from the blood in capillaries as the blood circulates in the body. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Cardiac Output After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) The volume of blood pumped per minute by each ventricle of the heart. Cardiac output is equal to the stroke volume (the amount of blood pumped from a ventricle in a single heartbeat) times the heart rate. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Stroke Volume After Study Drug (Resting) | Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Stroke volume is the amount of blood pumped out of the heart (left ventricle - to the body) during each contraction. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Central Pressures After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Heart Rate After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Blood Pressure After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in PVR After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Pulmonary Vascular Resistance (PVR) is the resistance to flow that must be overcome to push blood through the pulmonary vasculature. Acute and chronic lung disease can both cause an increase in PVR. Chronic PVR can lead to right sided heart failure. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in PA Compliance After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Pulmonary artery compliance is an index of the elasticity of the blood vessel, an indication of arterial stiffness. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in SVR After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Systemic vascular resistance (SVR) refers to the resistance to blood flow offered by all of the systemic vasculature, excluding the pulmonary vasculature. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in LVSW After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Stroke work refers to the work done by the ventricle to eject a volume of blood (i.e., stroke volume) into the aorta. Ventricular stroke work can be estimated as the product of stroke volume and mean aortic pressure during ejection. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Oxygen Consumption (VO_2) After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Arteriovenous Oxygen Difference After Study Drug (Exercise) | Arteriovenous oxygen difference is the difference in the oxygen content of the blood between the arterial blood and the venous blood. It is an indication of how much oxygen is removed from the blood in capillaries as the blood circulates in the body. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Cardiac Output After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Cardiac output is equal to the stroke volume (the amount of blood pumped from a ventricle in a single heartbeat) times the heart rate. | baseline, approximately 30 minutes after study drug administration | No |
Secondary | Change in Stroke Volume After Study Drug (Exercise) | Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Stroke volume is the amount of blood pumped out of the heart (left ventricle - to the body) during each contraction. | baseline, approximately 30 minutes after study drug administration | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A |